PA-25-306 NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)

Scope Note

Table of ICO-Specific Contacts and Information

NIH Institute or Center ContactsInstitute/Center Specific Information

National Center for Complementary and Integrative Health (NCCIH)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Email: [email protected]

 

National Cancer Institute (NCI)

Scientific Program Contacts:
Email:  [email protected]  

Grants Management Contact:
Email:  [email protected] 

 

National Eye Institute (NEI)

Scientific Program Contact:
E-mail: [email protected]

Grants Management Contact:
Email: [email protected]

Clinical trials involve studies in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. The NEI accepts applications for minimal risk clinical trials in its mission. Minimal participant risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests (45 CFR 46). Please see NOT-EY-23-001 for further information.

For an application that states that the study poses a minimal risk to participants, NEI may request verification from the applicant including the risk determination documentation from the FDA and IRBs prior to award. This will be outlined in the Notice of Award Terms and Conditions when applicable.

National Human Genome Research Institute (NHGRI)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Email: [email protected] 

In general, NHGRI supports studies that provide generalizable methods and knowledge. Approaches that are comprehensive across the genome or are generalizable across variants, tissues, diseases, or function may be in scope for NHGRI to the extent they address priority areas described in the NHGRI 2020 Strategic Vision: https://www.genome.gov/2020SV

Applications for studies relevant only to a particular disease or organ system should be directed to the appropriate Institute or Center. Applications whose primary scientific objective is to understand a single biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention do not fall under the mission of NHGRI.

National Institute on Aging (NIA)

Scientific Program Contacts:
Email:  [email protected]

Grants Management Contact:
Email: [email protected]

 

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Email:[email protected]

 

National Institute of Allergy and Infectious Diseases (NIAID)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Email: [email protected]  

Applicants proposing “high-risk” clinical trials should not submit to this NOFO.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Email: [email protected] 

 

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Cheif Grants Management Officer
Email: [email protected]

For this Notice of Funding Opportunity, NIBIB funding of clinical trials will be in accordance with NOT-EB-21-005 "NIBIB Guidance for Support of Clinical Trial Applications". Briefly, NIBIB will only support mission-focused early stage clinical trial applications, i.e., feasibility, Phase I, first-in-human, safety, or other small clinical trials, that inform early stage technology development. NIBIB will not support applications proposing pivotal, Phase II, III, IV, or trials in which the primary outcome is efficacy, effectiveness, or a post-market concern. Also, mechanistic trials are not supported unless the primary focus of the project is on technology development.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Scientific Program Contact:
Email: [email protected]

Grants Management Contact:
Email: [email protected]

 

National Institute on Drug Abuse (NIDA)

Scientific Program Contact:
Email: [email protected]       

Grants Management Contact:
Chief Grants Management Officer
Email: [email protected] 

 

National Institute on Deafness and Other Communication Disorders (NIDCD)

Scientific Program Contact:
Email: [email protected]

Grants Management Contact:
Email: [email protected]  

 

National Institute of Environmental Health Sciences (NIEHS)

Scientific Program Contact:
Email: [email protected]

Grants Management Contact:
Email: [email protected]

 

National Institute of Mental Health (NIMH)

 

Scientific Program Contact:

Email: [email protected] 

Division of Neuroscience and Basic Behavioral Science (DNBBS) 
Email: [email protected]  

Division of Translational Research (DTR) 
Email: [email protected]  

Division of AIDS Research (DAR) 
Email: [email protected]  

Division of Services and Intervention research (DSIR) 
Email: [email protected]  

Division of Data Science and Technology (DST) 
Email: [email protected]  

Grants Management Contact: 

Email: [email protected]   

As stated in NOT-MH-23-375, NIMH only accepts clinical trial applications proposing mechanistic studies under the Parent R21 Clinical Trial Required (PA-25-306).

National Institute of Nursing Research (NINR)

Scientific Program Contact:
Email: [email protected] 

Grants Management Contact:
Email: [email protected]

 

National Library of Medicine (NLM)

Scientific Program Contacts:
Email: [email protected]

Grants Management Contact:
Email:  [email protected]

 

This page last updated on: June 3, 2026
For technical issues E-mail OER Webmaster